IL21 and systemic sclerosis: Although further studies are needed to better clarify the possible pathogenetic role of IL-21 in SSc pathogenesis and progression, the results of our study may suggest that a possible treatment directed at the neutralization of this cytokine may be useful in addition to the currently available treatment approved for joint involvement in SSc patients.